Literature DB >> 12680257

Chemopreventive efficacy of suberoylanilide hydroxamic acid (SAHA) against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice.

Dhimant Desai1, Arunangshu Das, Leonard Cohen, Karam el-Bayoumy, Shantu Amin.   

Abstract

Histone deacetylase (HDAC) inhibitors, such as suberoylanilide hydroxamic acid (SAHA), represent a promising new class of chemopreventive agents. We have synthesized SAHA by an improved method and examined its efficacy as a dietary supplement at 450 ppm against lung tumor development in female A/J mice induced by the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). We observed significant inhibition (80%, p < 0.0001) of lung tumor multiplicity in mice treated with NNK plus SAHA compared to NNK-treated controls. SAHA inhibited the carbonyl reductive pathways of NNK in a dose-dependent manner in liver, but not lung microsomes, obtained from A/J mice. However, a significant inhibition of the a-hydroxylation pathway of NNK was observed in both lung and liver microsomes, suggesting that SAHA may act to inhibit the activation pathways of NNK metabolism. The results of this model study indicate that SAHA holds promise as a potential chemopreventive agent against lung cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12680257

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  12 in total

1.  Chemoprevention of mouse lung and colon tumors by suberoylanilide hydroxamic acid and atorvastatin.

Authors:  Michael A Pereira; Blake M Warner; Thomas J Knobloch; Christopher M Weghorst; Ronald A Lubet; Vernon E Steele; Bruce C Casto
Journal:  Int J Cancer       Date:  2012-01-31       Impact factor: 7.396

2.  Pendant HDAC inhibitor SAHA derivatised polymer as a novel prodrug micellar carrier for anticancer drugs.

Authors:  Jieni Xu; Jingjing Sun; Pengcheng Wang; Xiaochao Ma; Song Li
Journal:  J Drug Target       Date:  2017-12-27       Impact factor: 5.121

3.  SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors.

Authors:  Dhimant Desai; Ugur Salli; Kent E Vrana; Shantu Amin
Journal:  Bioorg Med Chem Lett       Date:  2009-07-17       Impact factor: 2.823

4.  Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells.

Authors:  Taofeek K Owonikoko; Suresh S Ramalingam; Beatriz Kanterewicz; Trent E Balius; Chandra P Belani; Pamela A Hershberger
Journal:  Int J Cancer       Date:  2010-02-01       Impact factor: 7.396

5.  Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer.

Authors:  Tian Ma; Fabrizio Galimberti; Cherie P Erkmen; Vincent Memoli; Fadzai Chinyengetere; Lorenzo Sempere; Jan H Beumer; Bean N Anyang; William Nugent; David Johnstone; Gregory J Tsongalis; Jonathan M Kurie; Hua Li; James Direnzo; Yongli Guo; Sarah J Freemantle; Konstantin H Dragnev; Ethan Dmitrovsky
Journal:  Mol Cancer Ther       Date:  2013-05-16       Impact factor: 6.261

6.  Expression of P53, P21 in human lung adenocarcinoma A549 cell strains under hypoxia conditions and the effect of TSA on their expression.

Authors:  Hong Huang; Zhenxiang Zhang; Yongjian Xu; Jingfang Shao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2003

7.  NNK-Induced Lung Tumors: A Review of Animal Model.

Authors:  Hua-Chuan Zheng; Yasuo Takano
Journal:  J Oncol       Date:  2011-04-27       Impact factor: 4.375

Review 8.  Targeting histone deacetylases for the treatment of disease.

Authors:  M W Lawless; S Norris; K J O'Byrne; S G Gray
Journal:  J Cell Mol Med       Date:  2008-11-03       Impact factor: 5.310

9.  Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat.

Authors:  Madeleine Duvic; Jenny Vu
Journal:  Biologics       Date:  2007-12

10.  Vorinostat-An Overview.

Authors:  Aditya Kumar Bubna
Journal:  Indian J Dermatol       Date:  2015 Jul-Aug       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.